SCHEMBL3517906

SCHEMBL3517906

CC1(C(=O)O)COc2ccccc2C1=O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.41
TSHR P16473 1/20 0.41
VKORC1 Q9BQB6 1/20 0.38
ALDH1A1 P00352 3/20 0.37
MEN1 O00255 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
KMT2A Q03164 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
PTGS1 P23219 1/20 0.37
PTGS2 P35354 1/20 0.37
CYP19A1 P11511 1/20 0.37
HPGD P15428 2/20 0.36
MAPT P10636 1/20 0.36
MAOB P27338 2/20 0.36
KDM4E B2RXH2 1/20 0.35
GAA P10253 1/20 0.35
MAPK1 P28482 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1991148 0.80 ALDH1A1 (0.47) TSHRALDH1A1MEN1CYP3A4CYP2C9
SCHEMBL1133012 0.78 PKM (0.47) PKMTSHRALDH1A1MEN1CYP3A4
SCHEMBL29448029 0.78 PKM (0.47) PKMTSHRALDH1A1MEN1CYP3A4
SCHEMBL2025120 0.75 PKM (0.42) PKMTSHRVKORC1ALDH1A1MEN1
SCHEMBL2107486 0.72 TSHR (0.42) PKMTSHRVKORC1ALDH1A1MEN1
SCHEMBL27188926 0.71 LMNA (0.47) TSHRALDH1A1CYP2D6NPSR1HPGD
Cyanide SCHEMBL27350268 0.71 PKM (0.41) PKMTSHRVKORC1ALDH1A1MEN1
SCHEMBL149892 0.71 ALDH1A1 (0.37) PKMTSHRALDH1A1MEN1CYP3A4
SCHEMBL2156976 0.71 APEX1 (0.44) PKMTSHRALDH1A1MEN1CYP3A4
SCHEMBL4618757 0.70 TSHR (0.47) PKMTSHRALDH1A1MEN1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7667053-B2 Cannabinoid-1 (CB1) receptor antagonists and/or inverse agonists; e.g. N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-1,4-benzodioxane-2-carboxamide; psychological disorders, eating disorders MERCK & CO., INC. (US) 2010-02-23 US disclosed
EP-1499306-A4 BICYCLIC AMIDES MERCK & CO INC (US) 2007-03-28 EP disclosed
US-20050203112-A1 Bicyclic amides MERCK SHARP & DOHME CORP. 2005-09-15 US disclosed
EP-1499306-A2 BICYCLIC AMIDES Merck & Co., Inc. (US) 2005-01-26 EP disclosed
WO-2003086288-A2 BICYCLIC AMIDES MERCK & CO., INC. (US) 2003-10-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203112-A1 Bicyclic amides CNR1, CNR2, FAAH PKM 4097/4885TSHR 974/4885VKORC1 2046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.